NGFR and melanoma: MNK1/2 inhibitors, which block eIF4E phosphorylation, decreased melanoma cell invasion, restored MITF expression and repressed NGFR expression in BRAFi-resistant cells, and cooperatively inhibited their growth in combination with vemurafenib (146).